For US Healthcare Professionals
logo VRX

Hospital Outcomes

Use of Voraxaze Leads to Reduced Length of Stay and Reduced Mortality Rates1

In a retrospective study of Medicare patients with cancer, patients treated with Voraxaze® (glucarpidase) had all of the following benefits compared with nonglucarpidase patients treated with dialysis (dialysis+) and nonglucarpidase patients with or without dialysis treatment (dialysis+/-), respectively1,*:

  • Shorter mean hospital length of stay (14.7 days vs 40.2 days and 21.9 days)
  • Shorter mean intensive care unit (ICU) length of stay (4.0 days vs 18.2 days in the dialysis+ group)
  • Lower inpatient mortality rates (3.3% vs 50.6% and 20.8%)
  • Lower 90-day mortality rates (16.7% vs 58.6% and 37.6%)

*Utilizing Medicare inpatient claims data between 2010 and 2017, investigators compared outcomes and healthcare resource utilization between patients treated with Voraxaze (n=30) and patients not treated with Voraxaze (n=701), all of whom had experienced acute kidney injury secondary to inpatient chemotherapy.1

Want More Detail?

Review the Full Article Online

Mean length of stay (LOS) among patients treated with Voraxaze and the non-Voraxaze groups1

Mean length of stay (LOS) among patients treated with Voraxaze and the non-Voraxaze groups


Source: ClinicoEconomics and Outcomes Research 2019:11 129-144. Adapted and used with permission from Dove Medical Press Ltd.


Rates of mortality among patients treated with Voraxaze and the non-Voraxaze groups1

Rates of mortality among patients treated with Voraxaze and the non-Voraxaze groups

Source: ClinicoEconomics and Outcomes Research 2019:11 129-144. Adapted and used with permission from Dove Medical Press Ltd.

Early vs Late Treatment With Voraxaze1

Length of stay in hospital was 54% shorter and ICU stay was 91% shorter with earlier administration of Voraxaze.


Early cohortLate cohort
Overall length of stay10.0 days21.7 days (P=0.002)
Length of hospital stay after Voraxaze8.5 days14.6 days (P=0.057)
Length of ICU stay0.8 days8.9 days (P=0.020)

Trust Voraxaze for Rapid and Sustained Reductions in MTX2

Not every patient requires Voraxaze, but experts have assembled recommendations to help guide treatment.

Explore guidelines for the use and stocking of Voraxaze so that you’re prepared in an emergency.

Get Guidance